Highlights include Sanofi-Aventis SA (SNY) and Johnson & Johnson (JNJ).On March 18th and 19th, the FDA advisory panels recommended approval of 2 important cardiovascular product candidates. The FDA does not have to follow the recommendations of the panels but usually does.On Wednesday, the 18th of March, an FDA advisory panel recommended approval of Sanofi-Aventis' (SNY) heart drug Multaq. Multaq (dronedarone) is a new class III anti-arrhythmic drug developed for atrial fibrillation (AF).On Thursday the 19th, an FDA review panel voted 15 to 2 in favor of approving Johnson & Johnson's (JNJ) anticoagulant rivaroxaban. Rivaroxaban, which will be sold under the brand name Xarelto upon approval, will be marketed in the U.S. by J&J and is already sold partner Bayer AG outside of the U.S. Multaq was initially submitted to the FDA for approval in 2006 but the FDA responded ...